drug
ribupatide
Phase 3updated 6mo agoby $KLRA Kailera Therapeutics, Inc.
Phase 3community read0 votes
indications
indications
Type 2 DiabetesObesity
all catalysts(0)
nothing on the calendar yet
Trials studying ribupatide
- phase3Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- phase3Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- phase3A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
- phase2Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
News(6)
- The 6 biggest crossover rounds in biopharma historyA strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.biospace · 27d ago
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 1mo ago
- Chutes & Ladders—Former Legend CEO lands at K2Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…fiercebiotech · 3mo ago
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…biospace · 3mo ago
- Kailera says obesity pill succeeds in late-stage trial in ChinaThe drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.biopharma_dive · 4mo ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that